Literature DB >> 11311500

The Cycloxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat.

S Govoni1, E Masoero, L Favalli, A Rozza, R Scelsi, S Viappiani, C Buccellati, A Sala, G Folco.   

Abstract

Focal ischemia was induced in the fronto-parietal region of rat brain, by injection of Rose Bengal, followed by light activation. Focal ischemia was accompanied by formation of PGD(2) peaking 60-90 min post irradiation and declining thereafter. Increased Cycloxygenase-2 (COX-2) expression was also observed. Control ischemic rats showed distinct morphological alterations with necrosis of neurons, glial cells and blood vessels, surrounded by a halo with pyknotic cells with cytoplasm swelling and vacuolization. Compound SC58236, a selective COX-2 inhibitor, dose-dependently prevented, ischemia-induced eicosanoid formation (area under the curve (AUC) of controls: 3.11 +/- 0.87; AUC of 20 mg/kg SC58236: 0.39 +/- 0.24), and caused significant reduction of damaged area (30.7 and 18.9% at SC58236 20 and 6.6 mg/kg), suggesting that selective inhibitors of COX-2 are neuroprotective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311500     DOI: 10.1016/s0304-3940(01)01675-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

1.  Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?

Authors:  A Abbate; D Santini; G G L Biondi-Zoccai; S Scarpa; F Vasaturo; G Liuzzo; R Bussani; F Silvestri; F Baldi; F Crea; L M Biasucci; A Baldi
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

Review 2.  Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism.

Authors:  J Davidson; D Rotondo; M T Rizzo; H A Leaver
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  The upregulation of zinc finger protein 670 and prostaglandin D2 synthase in proliferative vitreoretinopathy.

Authors:  Hsi-Kung Kuo; Yi-Hao Chen; Faye Huang; Yi-Chan Wu; Jentaie Shiea; Pei-Chang Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-05       Impact factor: 3.117

4.  Serum deprivation and re-addition: effects on cyclooxygenase inhibitor sensitivity in cultured glia.

Authors:  James Phillips; Brian Pearce
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

5.  Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity.

Authors:  Y Ikeda-Matsuo; Y Hirayama; A Ota; S Uematsu; S Akira; Y Sasaki
Journal:  Br J Pharmacol       Date:  2010-01-29       Impact factor: 8.739

Review 6.  Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury.

Authors:  Heena Khan; Kunal Sharma; Amit Kumar; Amarjot Kaur; Thakur Gurjeet Singh
Journal:  Inflamm Res       Date:  2022-02-17       Impact factor: 4.575

Review 7.  Anti-inflammatory agents in Alzheimer's disease.

Authors:  Paul S Aisen
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

8.  Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats.

Authors:  Rita I M Galvão; João P L Diógenes; Graziela C L Maia; Emídio A S Filho; Silvânia M M Vasconcelos; Dalgimar B de Menezes; Geanne M A Cunha; Glauce S B Viana
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

Review 9.  Nonsteroidal anti-inflammatory agents in neonates.

Authors:  John L Morris; David A Rosen; Kathleen R Rosen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 10.  Function of COX-2 and prostaglandins in neurological disease.

Authors:  X Liang; L Wu; Q Wang; T Hand; M Bilak; L McCullough; K Andreasson
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.